BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23470476)

  • 1. [Utility of a microdose study for drug discovery and development].
    Yamaura Y
    Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476
    [No Abstract]   [Full Text] [Related]  

  • 2. Concentration-controlled trials. What does the future hold?
    Johnston A; Holt DW
    Clin Pharmacokinet; 1995 Feb; 28(2):93-9. PubMed ID: 7736691
    [No Abstract]   [Full Text] [Related]  

  • 3. The utility of microdosing over the past 5 years.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdosing: current and the future.
    Lappin G
    Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
    Oosterhuis B
    Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
    Wagner CC; Langer O
    Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Rosenberger WF; Manukyan Z
    Stat Med; 2009 Dec; 28(30):3751-3; discussion 3759-60. PubMed ID: 19967756
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Atkinson AC
    Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary on 'Designs of dose-escalation trials with quantitative responses'.
    Haines LM
    Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictive Value of Microdose Pharmacokinetics.
    van Nuland M; Rosing H; Huitema ADR; Beijnen JH
    Clin Pharmacokinet; 2019 Oct; 58(10):1221-1236. PubMed ID: 31030372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human microdosing for the prediction of patient response.
    Henderson PT; Pan CX
    Bioanalysis; 2010 Mar; 2(3):373-6. PubMed ID: 21083245
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness analysis of microdose clinical trials in drug development.
    Yamane N; Igarashi A; Kusama M; Maeda K; Ikeda T; Sugiyama Y
    Drug Metab Pharmacokinet; 2013; 28(3):187-95. PubMed ID: 22971640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Senn S
    Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics and Dissemination of Phase 1 Trials Approved by a UK Regional Office in 2012.
    Odutayo A; Copsey B; Dutton S; Cook J; Hopewell S; Altman DG
    JAMA; 2017 May; 317(17):1799-1801. PubMed ID: 28464134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?
    Boyd RA; Lalonde RL
    Clin Pharmacol Ther; 2007 Jan; 81(1):24-6. PubMed ID: 17185993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.